Guggenheim began coverage on shares of IGM Biosciences (NASDAQ:IGMS) in a report released on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $30.00 target price on the stock.
Separately, Piper Jaffray Companies assumed coverage on IGM Biosciences in a research note on Sunday. They issued an overweight rating and a $26.00 price target for the company.
NASDAQ:IGMS opened at $18.64 on Monday. IGM Biosciences has a fifty-two week low of $16.10 and a fifty-two week high of $24.57.
IGM Biosciences Company Profile
IGM Biosciences, Inc, a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma.
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.